Philips is planning to invest at least $150 million in new funding for its U.S. production base, including through the ...

Experienced business developer Derek Hicks has been handed the reins of Rezo Therapeutics, his first time at the helm of a ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...

Shortly after welcoming a new CEO, robot developer Vicarious Surgical reported that it will be delaying the clinical trials ...

Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...